BeiGene, Ltd. (NASDAQ:BGNE) Receives $251.70 Consensus Target Price from Analysts

Shares of BeiGene, Ltd. (NASDAQ:BGNE) have been given a consensus recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $251.70.

Several equities research analysts have issued reports on the company. Sanford C. Bernstein dropped their price objective on BeiGene from $196.00 to $161.00 and set a “market perform” rating on the stock in a report on Wednesday, March 27th. JPMorgan Chase & Co. boosted their price target on BeiGene from $184.00 to $186.00 and gave the company an “overweight” rating in a report on Tuesday, March 19th. Guggenheim lowered their price target on BeiGene from $350.00 to $345.00 and set a “buy” rating for the company in a report on Tuesday, February 27th. Finally, Bank of America lowered their price target on BeiGene from $179.30 to $164.30 and set a “neutral” rating for the company in a report on Monday, April 8th.

Insider Activity at BeiGene

In related news, CEO John Oyler sold 26,716 shares of the firm’s stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $148.89, for a total transaction of $3,977,745.24. Following the completion of the transaction, the chief executive officer now owns 12,084 shares of the company’s stock, valued at $1,799,186.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CEO John Oyler sold 26,716 shares of the company’s stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $148.89, for a total transaction of $3,977,745.24. Following the completion of the sale, the chief executive officer now directly owns 12,084 shares of the company’s stock, valued at $1,799,186.76. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Julia Aijun Wang sold 397 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $167.08, for a total value of $66,330.76. The disclosure for this sale can be found here. Insiders sold 64,781 shares of company stock valued at $10,222,381 over the last 90 days. 7.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BeiGene

Hedge funds have recently bought and sold shares of the business. Toronto Dominion Bank lifted its stake in BeiGene by 166.4% in the 3rd quarter. Toronto Dominion Bank now owns 333 shares of the company’s stock worth $60,000 after acquiring an additional 208 shares in the last quarter. Knights of Columbus Asset Advisors LLC increased its position in BeiGene by 20.5% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 447 shares of the company’s stock worth $80,000 after purchasing an additional 76 shares during the last quarter. Benjamin F. Edwards & Company Inc. acquired a new position in BeiGene in the 4th quarter worth about $98,000. PNC Financial Services Group Inc. increased its position in BeiGene by 123.9% in the 3rd quarter. PNC Financial Services Group Inc. now owns 732 shares of the company’s stock worth $132,000 after purchasing an additional 405 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in BeiGene in the 4th quarter worth about $183,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

BeiGene Stock Performance

NASDAQ BGNE opened at $138.99 on Friday. The firm has a market capitalization of $13.29 billion, a P/E ratio of -16.35 and a beta of 0.61. BeiGene has a 1-year low of $126.97 and a 1-year high of $266.67. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.32 and a quick ratio of 2.09. The business’s 50-day simple moving average is $154.71 and its 200-day simple moving average is $167.69.

BeiGene (NASDAQ:BGNE) last announced its earnings results on Monday, February 26th. The company reported ($3.53) EPS for the quarter, beating the consensus estimate of ($3.61) by $0.08. The business had revenue of $634.40 million for the quarter, compared to the consensus estimate of $632.52 million. BeiGene had a negative return on equity of 23.12% and a negative net margin of 35.86%. The company’s revenue was up 66.9% on a year-over-year basis. During the same period last year, the business posted ($4.29) EPS. Equities analysts predict that BeiGene will post -8.87 EPS for the current year.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.